Active surveillance for low-risk prostate cancer: Need for intervention and survival at 10 years

Abstract

IntroductionTo describe the need for treatment and cancer-specific and overall survival in a contemporary active surveillance (AS) cohort. Patients and methodsHistorical cohort study of men diagnosed with localized prostate cancer between 1997 and 2009 and managed with AS at a tertiary care center. Inclusion criteria were Gleason score≤6 (Gleason score of 7 in select patients),≤3/12 cores positive, and prostate-specific antigen (PSA) level<20ng/ml. Survival analyses were conducted using the Kaplan-Meier method. ResultsA total of 469 men with median age at diagnosis of 68.1 years (interquartile range [IQR]: 62.5–73.4) were followed up for a median of 4.8 years (IQR: 3.4–7.3). Median PSA level at diagnosis was 5.1ng/ml (IQR: 4.0–6.9), with 94% of them having PSA level<10ng/ml. Overall, 98.3% (461/469) of patients had a Gleason score of 6 and 1.7% (8/469) had a Gleason score of 3+4 = 7, and 94.0% (441/469) had T1c stage disease. Freedom from treatment was 77% at 5 years and 62% at 10 years. A total of 116 (24.7%) patients received treatment during the course of surveillance. Reasons for treatment included 44.8% (52/116) for pathologic reclassification, 30.2% (35/116) for PSA progression, 12.1% (14/116) for patient preference, 5.2% (6/116) for digital rectal examination progression, and 4.3% (5/116) for metastatic disease. Of the patients treated, 59 (50.1%) received radiation, 26 (22.4%) underwent surgery, 17 (14.7%) received brachytherapy, and 14 (12.1%) received androgen-deprivation therapy. Cancer-specific survival was 100% at 5 and 10 years. Overall survival was 95% at 5 years and 88% at 10 years. ConclusionIn a contemporary cohort of men with low-risk prostate cancer, AS allowed avoidance of treatment most of them. Common reasons for change in management were Gleason upgrading and volume progression on prostate rebiopsy.